Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

Authors

Viola Tozzi
Corrado Bernasconi (ORCID: https://orcid.org/0000-0002-1019-5468)
Sean Yiu (ORCID: https://orcid.org/0000-0002-8345-3632)
Licínio Craveiro (ORCID: https://orcid.org/0000-0002-8841-8035)
Yanic Heer
Philip van Hövell
Erwan Muros‐Le Rouzic (ORCID: https://orcid.org/0000-0002-8925-0481)
Fabian Model (ORCID: https://orcid.org/0009-0002-6319-9902)
Stefan Braune (ORCID: https://orcid.org/0000-0002-0541-8196)
Arnfin Bergmann

Institutions

Roche (Switzerland) (CH)
Union Bank of Switzerland (CH)
Roche (United Kingdom) (GB)

Publication Details

Journal: Journal of Central Nervous System Disease
Published: 2024-09-13
DOI: https://doi.org/10.1177/11795735241260563
Citations: 3
Primary Topic: Multiple Sclerosis Research Studies
Type: article
Field-Weighted Citation Impact: 1.27

Funders

Biogen
F. Hoffmann-La Roche
Servier

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

Viola Tozzi, Corrado Bernasconi, Sean Yiu, Licínio Craveiro et al.

Sep 13, 2024

3 citations

Journal of Central Nervous System Disease

Multiple Sclerosis Research Studies

1.27

article

Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

Viola Tozzi, Corrado Bernasconi, Sean Yiu, Licínio Craveiro, Yanic Heer, Philip van Hövell, Erwan Muros‐Le Rouzic, Fabian Model, Stefan Braune, Arnfin Bergmann

September 13, 2024article en

3 citations

Abstract

No abstract available for this paper.

Journal of Central Nervous System DiseaseVol. 16

Roche (Switzerland) (CH), Union Bank of Switzerland (CH), Roche (United Kingdom) (GB)

Biogen, F. Hoffmann-La Roche, Servier

Openalex Percentile: Top 20%

Multiple Sclerosis Research Studies

1.27

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.